AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease (HD), scientists have ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

Michigan-based clinical research organization MMS is boosting its data science power with a new purchase from the U.K. The ...

A federal judge has issued a temporary pause across all states on the new NIH order that caps “indirect costs” for research ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving ...